Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1950 3
1951 1
1955 1
1999 1
2002 1
2012 2
2013 6
2014 17
2015 23
2016 26
2017 24
2018 37
2019 45
2020 35
2021 26
2022 37
2023 35
2024 35
2025 19

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

330 results

Results by year

Filters applied: . Clear all
Page 1
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö, Salles G, Maziarz RT; JULIET Investigators. Schuster SJ, et al. N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1. N Engl J Med. 2019. PMID: 30501490 Clinical Trial.
Foreword.
Lapa C, Bundschuh RA. Lapa C, et al. Nuklearmedizin. 2022 Jun;61(3):222. doi: 10.1055/a-1819-9945. Epub 2022 Jun 3. Nuklearmedizin. 2022. PMID: 35668667 No abstract available.
Long-Term Nephrotoxicity of 177Lu-PSMA Radioligand Therapy.
Steinhelfer L, Lunger L, Cala L, Pfob CH, Lapa C, Hartrampf PE, Buck AK, Schäfer H, Schmaderer C, Tauber R, Brosch-Lenz J, Haller B, Meissner VH, Knorr K, Weber WA, Eiber M. Steinhelfer L, et al. Among authors: lapa c. J Nucl Med. 2024 Jan 2;65(1):79-84. doi: 10.2967/jnumed.123.265986. J Nucl Med. 2024. PMID: 37857504 Free article.
Response.
Emmanuel A, Lapa C, Ghosh A, Gulati S, Burt M, Hayee B, Haji A. Emmanuel A, et al. Among authors: lapa c. Gastrointest Endosc. 2019 Sep;90(3):542. doi: 10.1016/j.gie.2019.05.017. Gastrointest Endosc. 2019. PMID: 31439145 No abstract available.
Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings.
Hummel HD, Kufer P, Grüllich C, Seggewiss-Bernhardt R, Deschler-Baier B, Chatterjee M, Goebeler ME, Miller K, de Santis M, Loidl W, Dittrich C, Buck A, Lapa C, Thurner A, Wittemer-Rump S, Koca G, Boix O, Döcke WD, Finnern R, Kusi H, Ajavon-Hartmann A, Stienen S, Sayehli CM, Polat B, Bargou RC. Hummel HD, et al. Among authors: lapa c. Immunotherapy. 2021 Feb;13(2):125-141. doi: 10.2217/imt-2020-0256. Epub 2020 Nov 10. Immunotherapy. 2021. PMID: 33172323 Free article. Clinical Trial.
Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms Using 68Ga-Pentixafor PET.
Buck AK, Haug A, Dreher N, Lambertini A, Higuchi T, Lapa C, Weich A, Pomper MG, Wester HJ, Zehndner A, Schirbel A, Samnick S, Hacker M, Pichler V, Hahner S, Fassnacht M, Einsele H, Serfling SE, Werner RA. Buck AK, et al. Among authors: lapa c. J Nucl Med. 2022 Nov;63(11):1687-1692. doi: 10.2967/jnumed.121.263693. Epub 2022 Mar 3. J Nucl Med. 2022. PMID: 35241482 Free article.
330 results